Clarametyx touts biofilm study

By The Science Advisory Board staff writers

November 5, 2021 -- Clarametyx Biosciences touted the results of a study published November 3 in Cell that provides insight about components in bacterial biofilms that drive resistance to current medicines.

The research aimed to understand the development and maturation of biofilms to better understand their resistance to the innate immune system. Researchers found that Z-form extracellular DNA (eDNA) is a structural component of the bacterial biofilm matrix (Cell, November 3, 2021).

The company said these findings suggest that the development of therapeutic agents designed to drive biofilm eDNA back into its native B form could prevent or resolve biofilm-mediated diseases.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter